WallStSmart

Aquestive Therapeutics Inc (AQST)vsZoetis Inc (ZTS)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Zoetis Inc generates 19340% more annual revenue ($9.49B vs $48.84M). ZTS leads profitability with a 26.4% profit margin vs -162.3%. ZTS earns a higher WallStSmart Score of 56/100 (C).

AQST

Avoid

18

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 4.0Quality: 6.5
Piotroski: 2/9Altman Z: -4.23

ZTS

Buy

56

out of 100

Grade: C

Growth: 3.3Profit: 9.5Value: 5.3Quality: 6.5
Piotroski: 4/9Altman Z: 3.14
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AQSTSignificantly Overvalued (-52.8%)

Margin of Safety

-52.8%

Fair Value

$2.50

Current Price

$3.46

$0.96 premium

UndervaluedFair: $2.50Overvalued
ZTSUndervalued (+11.0%)

Margin of Safety

+11.0%

Fair Value

$144.57

Current Price

$79.11

$65.46 discount

UndervaluedFair: $144.57Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AQST1 strengths · Avg: 10.0/10
Debt/EquityHealth
-0.1110/10

Conservative balance sheet, low leverage

ZTS5 strengths · Avg: 9.4/10
Return on EquityProfitability
75.3%10/10

Every $100 of equity generates 75 in profit

Operating MarginProfitability
38.2%10/10

Strong operational efficiency at 38.2%

Altman Z-ScoreHealth
3.1410/10

Safe zone — low bankruptcy risk

Profit MarginProfitability
26.4%9/10

Keeps 26 of every $100 in revenue as profit

P/E RatioValuation
14.0x8/10

Attractively priced relative to earnings

Areas to Watch

AQST4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$491.44M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

ZTS4 concerns · Avg: 2.5/10
Price/BookValuation
9.8x4/10

Trading at 9.8x book value

PEG RatioValuation
14.782/10

Expensive relative to growth rate

Revenue GrowthGrowth
-1.3%2/10

Revenue declined 1.3%

EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : AQST

The strongest argument for AQST centers on Debt/Equity.

Bull Case : ZTS

The strongest argument for ZTS centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 26.4% and operating margin at 38.2%.

Bear Case : AQST

The primary concerns for AQST are EPS Growth, Market Cap, Return on Equity.

Bear Case : ZTS

The primary concerns for ZTS are Price/Book, PEG Ratio, Revenue Growth. Debt-to-equity of 2.80 is elevated, increasing financial risk.

Key Dynamics to Monitor

AQST profiles as a turnaround stock while ZTS is a declining play — different risk/reward profiles.

AQST carries more volatility with a beta of 1.50 — expect wider price swings.

ZTS is growing revenue faster at -1.3% — sustainability is the question.

ZTS generates stronger free cash flow (717M), providing more financial flexibility.

Bottom Line

ZTS scores higher overall (56/100 vs 18/100), backed by strong 26.4% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Aquestive Therapeutics Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and marketing various products to address unmet medical needs in the United States and internationally. The company is headquartered in Warren, New Jersey.

Zoetis Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.

Visit Website →

Want to dig deeper into these stocks?